Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients with Myelofibrosis.

November 3, 2011
DOI: 10.4016/36039.01
883 views
URL
Embed
Share

Please describe the reason for abuse:



Description:
Dr. Animesh Pardanani, Assistant Professor of Medicine and Consultant in the Division of Hematology at Mayo Clinic in Rochester, MN, Discusses his... » More
Authors:
Animesh Pardanani, Ayalew Tefferi